ALKEM Q2 Results: Revenue declined by 0.73% year-over-year (YoY) to Rs. 3415 crore, while net profit rose by 14.15% YoY to Rs. 702 crore.
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
Revenue
Revenue for the current quarter (Sep 2024) is Rs. 3415.00 crore which is Rs. 3032.00 crore more than the revenue in the previous quarter (Jun 2024). However, it is lower than the revenue for the same quarter last year (Sep 2023) which was Rs. 3440.00 crore.
Net Profit
Net Profit for the current quarter (Sep 2024) is Rs. 702.00 crore, which is Rs. 550.00 crore more than the net profit in the previous quarter (Jun 2024). However, compared to the same quarter last year, it is significantly higher than the net profit of Rs. 615.00 crore for Sep 2023.
Profit Margin
The profit margin for the current quarter (Sep 2024) is 22%, which is 20% more than the profit margin for the previous quarter (Jun 2024). However, compared to the same quarter last year, the profit margin remains unchanged at 22%, as it was in Sep 2023.
EPS
The EPS for the current quarter (Sep 2024) is 57.60, which is 45.60 EPS for the previous quarter (Jun 2024). However, compared to the same quarter last year, it is higher than the EPS of 51.90 for Sep 2023.
Other Income
Other income for the current quarter (Sep 2024) is Rs. 134.00 crore, which is Rs. 120.00 crore other income for the previous quarter (Jun 2024). However, compared to the same quarter last year, it is higher than the other income of Rs. 6.00 crore for Sep 2023.